(NASDAQ:GOBI)
CorMedix Says Was Informed By Contract Manufacturer That There Are Issues Unrelated To DefenCath Manufacturing Activities; Timeline For Co. and CMO To Address Deficiencies That Are Required For Resubmission Of DefenCath NDA Is Uncertain
CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update
